Literature DB >> 18272622

Do you approve of spending $300 million on HPV vaccination?: yes.

Marc Steben1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18272622      PMCID： PMC2278296     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  10 in total

Review 1.  Chapter 2: The burden of HPV-related cancers.

Authors:  D Maxwell Parkin; Freddie Bray
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

Review 2.  Process of care failures in invasive cervical cancer: systematic review and meta-analysis.

Authors:  Andrea R Spence; Patricia Goggin; Eduardo L Franco
Journal:  Prev Med       Date:  2007-06-22       Impact factor: 4.018

3.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Authors:  Xavier Castellsagué; Mireia Díaz; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Rosanna W Peeling; Rhoda Ashley; Jennifer S Smith; Peter J F Snijders; Chris J L M Meijer; F Xavier Bosch
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

4.  Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis.

Authors:  Lisa E Manhart; Laura A Koutsky
Journal:  Sex Transm Dis       Date:  2002-11       Impact factor: 2.830

Review 5.  Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.

Authors:  Gary Clifford; Silvia Franceschi; Mireia Diaz; Nubia Muñoz; Luisa Lina Villa
Journal:  Vaccine       Date:  2006-06-02       Impact factor: 3.641

Review 6.  Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.

Authors:  Gary M Clifford; Rashida K Rana; Silvia Franceschi; Jennifer S Smith; Gerald Gough; Jeanne M Pimenta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

7.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Authors:  Michelle J Khan; Philip E Castle; Attila T Lorincz; Sholom Wacholder; Mark Sherman; David R Scott; Brenda B Rush; Andrew G Glass; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

8.  Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.

Authors:  Sven-Eric Olsson; Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Christian Malm; Ole-Erik Iversen; John Høye; Margareta Steinwall; Grete Riis-Johannessen; Agneta Andersson-Ellstrom; Kristina Elfgren; Geo von Krogh; Matti Lehtinen; Jorma Paavonen; Gretchen M Tamms; Katherine Giacoletti; Lisa Lupinacci; Mark T Esser; Scott C Vuocolo; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

9.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

10.  Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  CMAJ       Date:  2007-08-20       Impact factor: 8.262
  10 in total
  2 in total

1.  Rebuttal: Do you approve of spending $300 million on HPV vaccination? No.

Authors:  Abby Lippman; Madeline Boscoe; Carol Scurfield
Journal:  Can Fam Physician       Date:  2008-03       Impact factor: 3.275

2.  Including males in Canadian human papillomavirus vaccination programs: a policy analysis.

Authors:  Gilla K Shapiro; Samara Perez; Zeev Rosberger
Journal:  CMAJ       Date:  2016-04-25       Impact factor: 8.262
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.